Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis. Orbactiv mainly inhibits bacterial transglycosylase, which is the enzyme that forms the glycan backbone of the cell wall. Secondly, it inhibits transpeptidase, an enzyme that cross-links adjacent glycan strands to form the cell wall. Orbactiv has demonstrated in vitro bactericidal activity against a wide range of Gram-positive bacterial strains. It has demonstrated potency against vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). Moreover, it is active against both the VanA and VanB phenotypes of vancomycin-resistant enterococcus (VRE). Orbactiv’s enhanced efficacy stems partially from its additional ability to directly disrupt the bacterial cell wall and increase its permeability.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Orbactiv : Skin and skin structure infections
LIST OF FIGURES
10 Figure 1: Orbactiv’s SWOT analysis in cSSSI
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Orbactiv in cSSSI
12 Figure 3: Datamonitor Healthcare’s drug assessment summary for Orbactiv in cSSSI
LIST OF TABLES
4 Table 1: Orbactiv’s drug profile in ABSSSI
6 Table 2: Overview of pivotal trial data for Orbactiv in ABSSSI
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.